Characteristics of Patients treated with Immunotherapy alone or in combination with other therapies
The AIET has been administered with and without combination of other treatments in Lung cancer, Breast cancer, Stomach cancer, Uterus cancer, Head and neck cancer, Liver cancer, Prostate cancer, Rectal cancer, Esophagus cancer, Malignant melanoma(1), Multiple myeloma (2).
A male patient aged 40 years with Stage III (advanced) adenocarcinoma of the pancreas was given three transfusions of expanded NK and Cytotoxic T Lymphocytes along with surgery and adjuvant chemotherapy by NCRM. There was considerable improvement in the quality of life of the patient after the first transfusion which made the patient to take two more cycles of the AIET. The patient showed steady improvement with a significant tumor response proven by a steady decrease in tumour marker CA 19-9 values from 3800 -750 and a tumour progression-free survival of 18 months (3)
In one study 28 patients with inoperable advanced tumour of pancreas Immuno-cell therapy was given along with chemotherapy and these patients had a 50% survival time of 15.8 months(4)
Forty-four patients with stage IV gastric cancer assigned to the control group (chemotherapy alone) or immunotherapy plus chemotherapy group. The 50% survival rates were 11.5 and 8.3 months in the Immunotherapy and control groups, respectively (5)